292 related articles for article (PubMed ID: 20676275)
1. Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.
Cubeddu LX
Curr Cardiol Rev; 2009 Aug; 5(3):166-76. PubMed ID: 20676275
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.
Cubeddu LX
Curr Cardiol Rev; 2016; 12(2):141-54. PubMed ID: 26926294
[TBL] [Abstract][Full Text] [Related]
3. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
4. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
5. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
Antzelevitch C
J Electrocardiol; 2001; 34 Suppl():177-81. PubMed ID: 11781953
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced torsade de pointes: from molecular biology to bedside.
Tamargo J
Jpn J Pharmacol; 2000 May; 83(1):1-19. PubMed ID: 10887935
[TBL] [Abstract][Full Text] [Related]
7. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Witchel HJ; Hancox JC
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
[TBL] [Abstract][Full Text] [Related]
8. Contribution of haemodynamic side effects and associated autonomic reflexes to ventricular arrhythmias triggering by torsadogenic hERG blocking drugs.
Champéroux P; Fares R; Bastogne T; Richard S; Le Guennec JY; Thireau J
Br J Pharmacol; 2022 Sep; 179(18):4549-4562. PubMed ID: 35751378
[TBL] [Abstract][Full Text] [Related]
9. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Shimizu W; Antzelevitch C
Circulation; 1998 Nov; 98(21):2314-22. PubMed ID: 9826320
[TBL] [Abstract][Full Text] [Related]
10. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
11. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.
Antzelevitch C
Heart Rhythm; 2005 Nov; 2(2 Suppl):S9-15. PubMed ID: 16253930
[TBL] [Abstract][Full Text] [Related]
12. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.
Cubeddu LX
Am J Ther; 2003; 10(6):452-7. PubMed ID: 14624285
[TBL] [Abstract][Full Text] [Related]
13. In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Romero L; Trenor B; Yang PC; Saiz J; Clancy CE
J Mol Cell Cardiol; 2014 Jul; 72():126-37. PubMed ID: 24631769
[TBL] [Abstract][Full Text] [Related]
14. Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome.
Antzelevitch C; Yan GX; Shimizu W
J Electrocardiol; 1999; 32 Suppl():158-65. PubMed ID: 10688320
[TBL] [Abstract][Full Text] [Related]
15. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
Katchman AN; Koerner J; Tosaka T; Woosley RL; Ebert SN
J Pharmacol Exp Ther; 2006 Mar; 316(3):1098-106. PubMed ID: 16278312
[TBL] [Abstract][Full Text] [Related]
17. Cardiac hERG K
Su S; Sun J; Wang Y; Xu Y
Handb Exp Pharmacol; 2021; 267():139-166. PubMed ID: 33829343
[TBL] [Abstract][Full Text] [Related]
18. Antiviral and anti-inflammatory drugs to combat COVID-19: Effects on cardiac ion channels and risk of ventricular arrhythmias.
Cubeddu LX; de la Rosa D; Ameruoso M
Bioimpacts; 2022; 12(1):9-20. PubMed ID: 35087712
[No Abstract] [Full Text] [Related]
19. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Rajamani S; Eckhardt LL; Valdivia CR; Klemens CA; Gillman BM; Anderson CL; Holzem KM; Delisle BP; Anson BD; Makielski JC; January CT
Br J Pharmacol; 2006 Nov; 149(5):481-9. PubMed ID: 16967046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
